NovaBridge and the $183 Million Reset: Three Drugs, No Revenue, and a Unanimous Street

August 28, 2024, was the day I-Mab ceased to exist as the company the market thought it knew. That morning, the NASDAQ-listed biotech announced the completion of a transaction it had first disclosed in April: the divestiture of its entire China operations. In one stroke, $183 million in redemption obligations, liabilities tied to a previous round of investment in the company's former China subsidiary, were extinguished. They did not have to be paid. They were simply gone. For a company that had spent the previous year under existential financial pressure, the arithmetic was stark: a liability equal to multiples of the company's market capitalization at the time had been removed from the ledger without a cash outlay.

The same day, interim CEO Sean Fu addressed investors on an earnings call. 'So far this year, 2024 has been transformational for I-MAB,' he said. The word was not hyperbole, but it was also incomplete. A transformation implies change that preserves something of the original. What occurred on August 28 was closer to a dissolution and reconstitution. The company had shed its China operations, the geographic and operational foundation on which it had been built since its founding in 2014. It had shed its founding identity. And it had shed its legacy pipeline beyond the three oncology assets that would form the core of its future.

The leadership team that stood behind Fu on that call was almost entirely new. Raj Kannan, who had been appointed CEO in June 2023 with a mandate to execute a three-point turnaround plan, was no longer there. In his place sat Fu himself, a board director elevated to interim CEO and later made permanent, alongside Phillip Dennis as Chief Medical Officer and Joe Skelton as Chief Financial Officer. All three had joined in 2024. None had been part of the company's prior incarnation. The old I-Mab management, the old I-Mab board, the old I-Mab strategy: all had been replaced or rendered moot by the divestiture.

Sixteen months later, in October 2025, the company completed the symbolic dimension of the break: it changed its name from I-Mab to NovaBridge Biosciences. 'Nova' for new, 'Bridge' for the clinical and regulatory pathway the company intends to build from its three oncology programs to the patients it hopes to serve. The name change was the final acknowledgment that the old company was gone and would not be coming back. What remained was a question: whether three clinical-stage immuno-oncology assets, a newly assembled American management team, and a balance sheet that would soon demonstrate its own dramatic volatility could carry the company to value-creating milestones before the remaining cash ran out.

To understand the scale of what was discarded, it is necessary to understand what I-Mab was. Founded in 2014, the company was built from the outset as a China-centric biotech. Its business model was straightforward: in-license drug candidates, develop them through clinical trials in China using the country's lower-cost clinical infrastructure, and aim for approvals in the world's second-largest pharmaceutical market. It was a model predicated on geography. The China opportunity was the thesis.

On January 17, 2020, I-Mab listed on the NASDAQ. The timing was propitious: the IPO window was open, investor appetite for China biotech was strong, and the company could present itself as a bridge between Western drug discovery and Chinese clinical development. The years that followed brought the accumulation of a pipeline that spanned immunology, oncology, and rare disease, a breadth that suggested ambition but also a certain lack of focus. The most advanced asset, eftansomatropin alfa, a long-acting human growth hormone, delivered positive Phase 3 results in August 2023. By any conventional measure, this was good news: a late-stage asset had cleared the bar. But the asset was tied to the China business, and the China business was becoming untenable.

By mid-2023, the board had reached a conclusion: the China-centric model was no longer viable. The specific pressures are not detailed in public filings, but the remedy was radical. Raj Kannan, appointed CEO in June 2023, articulated a three-point plan that would define the transition: 'We plan to rapidly advance our two promising clinical assets globally within oncology. Two, maintain our strong balance sheet. And three, focus on establishing a new operating model to become a US-based global biotech company.' The language was careful, but the implication was not: the company would abandon its founding geography.

The divestiture that followed in 2024 was not merely a transaction. It was a severance. The China operations, encompassing the legacy pipeline, the clinical infrastructure, the regulatory relationships, and the personnel, were carved out. The $183 million in redemption obligations that had hung over the balance sheet were tied to the divested entity and extinguished. The company that emerged on the other side bore the same ticker but was, in every operational sense, a new entity. The decision to amputate rather than attempt rehabilitation was a judgment about time: the board appears to have concluded that fixing the old company would take longer than starting over. Whether that judgment was correct is the question that NovaBridge's three remaining assets must now answer.

NovaBridge exists today for one reason: the belief that three clinical-stage immuno-oncology programs can generate data compelling enough to attract partnership capital, regulatory approvals, or both. The assets are uliledlimab, givastomig, and ragistomig. Together they represent a focused bet on the proposition that targeting the adenosine pathway and co-stimulatory receptors can produce cancer therapies that matter. If they fail, there is no backup. The legacy pipeline was left behind in China.

Uliledlimab is a monoclonal antibody targeting CD73, an enzyme that sits on the surface of tumor cells and produces adenosine, a molecule that suppresses the immune system's ability to attack cancer. By blocking CD73, uliledlimab aims to remove that suppression, allowing T-cells to do their job. The CD73 pathway has attracted significant industry interest because it operates downstream of the checkpoint inhibitors that revolutionized oncology but still leaves most patients without durable responses. Uliledlimab is the most advanced of NovaBridge's three assets and the one on which the near-term clinical narrative turns.

Givastomig is a bispecific antibody that targets Claudin 18.2, a protein expressed on gastric and pancreatic cancer cells, while simultaneously engaging 4-1BB, a co-stimulatory receptor on immune cells. The dual mechanism is designed to concentrate immune activation at the tumor site rather than systemically, a strategy that aims to deliver efficacy without the toxicity that has historically limited 4-1BB-targeting drugs. Claudin 18.2 has become a closely watched target in oncology, and givastomig positions NovaBridge in a competitive but potentially high-reward space.

Ragistomig, the third asset, pairs PD-L1 targeting with 4-1BB co-stimulation, a different bispecific combination that aims to achieve what the company describes as 'conditional' immune activation. The logic is that by requiring both targets to be engaged simultaneously, ragistomig can activate T-cells only in the presence of PD-L1-expressing tumors, theoretically sparing healthy tissue. Like givastomig, it represents what has become a central theme in bispecific antibody development: the pursuit of tumor-localized immune activation.

None of these programs are being developed in isolation. NovaBridge has structured strategic collaborations to share the cost and risk of clinical development. Bristol Myers Squibb is the most significant partner, providing both validation and resources. ABL Bio and TJ Bio, both South Korean biotechs, round out the collaboration network. The partnerships serve a dual function: they offset the financial burden of clinical development for a company that generates zero revenue, and they signal that larger, better-capitalized organizations see sufficient promise in the science to write checks. For a pre-revenue biotech with $30 million in cash, the partner network is not a nice-to-have. It is a structural necessity.

Phillip Dennis, who joined as Chief Medical Officer in 2024, brings more than a decade of immuno-oncology experience to the task of shepherding these three assets through clinical development. His arrival, alongside the broader leadership reset, was part of the board's bet that a US-based team with deep domain expertise could execute more effectively than the legacy China-centric organization. Whether that bet pays off will be determined not by resumes but by clinical data. Dennis's tenure will be measured in trial readouts.

NovaBridge is a pre-revenue biotechnology company. This is not a temporary condition; it is the structural reality of an organization whose only assets are molecules in clinical trials. Revenue was $0 in every quarter of 2025: Q1, Q2, Q3, and Q4. There is no product on the market, no royalty stream, no licensing income that registers on the income statement. The company's financial existence depends entirely on its ability to raise capital from investors willing to bet on clinical data that has not yet materialized.

The cash balance tells the story that matters most. At the end of Q2 2025, NovaBridge held $165.6 million in cash and short-term investments, a manageable but declining buffer for a company burning $5 million to $7 million per quarter. Three months later, at the end of Q3, the cash balance stood at $1,625.2 million. The nearly tenfold increase was driven by $433.4 million in net cash from financing activities during the quarter, almost certainly a large equity raise or structured financing that flooded the balance sheet. Then, in Q4, the cash balance collapsed to $30.1 million. The whiplash, from $165 million to $1.6 billion to $30 million in three consecutive quarters, is almost certainly a function of how the Q3 financing was structured and subsequently allocated, but the available disclosures do not provide a complete explanation.

Net losses across 2025 were modest by biotech standards but trending in the wrong direction through the first three quarters: $3.2 million in Q1, $5.5 million in Q2, and $6.8 million in Q3, before dropping to $4.4 million in Q4. Free cash flow, which had been flat at $0 in the first half of the year, turned positive at $13.1 million in Q3, likely reflecting the financing inflow, before swinging to negative $14.6 million in Q4. The Q4 free cash flow figure, annualized, would suggest a cash consumption rate of roughly $58 million per year, though quarterly variability makes extrapolation hazardous.

Total debt stood at $0.44 million as of December 31, 2025, against a cash position of $30.1 million, yielding a net cash position of $29.7 million. The near-total absence of debt is a feature, not a footnote: it means the company has not encumbered its assets and retains financial flexibility. But flexibility is not the same as sufficiency. At current burn rates, the $30.1 million in cash provides a runway measured in quarters, not years. Joe Skelton, the CFO who joined in 2024 alongside the rest of the new leadership team, brings an investment banking background to the task of capital allocation, a skillset that will be tested repeatedly in the quarters ahead. Every financing event, from the Q3 2025 surge onward, is both a lifeline and a signal. The company can raise capital. The question is at what cost, and for how long.

All 11 analysts covering NovaBridge Biosciences rate the stock a Buy. Not a single Hold. Not a single Sell. Eleven Buys. For a pre-revenue biotech with $30 million in cash, three clinical-stage assets, and a corporate history defined by a radical break from its past, the unanimity is striking. It is also worth understanding what, exactly, a Buy rating on NovaBridge means, and what it does not.

A Buy rating on a pre-revenue biotech is not a judgment about current financials, because there are no current financials to judge beyond cash consumption and runway. It is a bet on the probability-weighted value of the pipeline. Specifically, it is a bet that at least one of the three core assets, uliledlimab, givastomig, or ragistomig, will generate clinical data sufficiently compelling to justify a partnership, an acquisition, or, in the most optimistic scenario, a path to regulatory approval. The analysts are not betting on quarterly earnings beats. They are betting on trial readouts that may be months or years away.

The key catalysts are straightforward. For uliledlimab, the CD73 antibody, any clinical data demonstrating activity in tumor types where checkpoint inhibitors have been inadequate would validate the adenosine-pathway thesis and position the asset for partnership discussions. For givastomig, the Claudin 18.2 bispecific, data in gastric or pancreatic cancer would place NovaBridge in a competitive field where positive readouts have historically attracted significant deal activity. For ragistomig, the PD-L1 x 4-1BB bispecific, the watch item is safety: can conditional T-cell activation deliver efficacy without the liver toxicity that has plagued earlier 4-1BB programs.

Sean Fu's strategic vision, a US-based global biotech focused on immuno-oncology and advancing assets through partnerships, is coherent. The China divestiture removed a set of liabilities and complexities that had made the old I-Mab difficult for Western investors to underwrite. The analyst unanimity suggests the market understands the thesis. But understanding and conviction are not the same thing, and conviction in biotech is ultimately a function of data. NovaBridge has made the clean break its board judged necessary. It has assembled the assets, the leadership, and, through the Q3 2025 financing, demonstrated an ability to raise capital. What it does not yet have is clinical proof that any of its three drugs works well enough to justify the bet. That proof, when it comes or does not, will render the verdict on the $183 million reset.